These findings underscore RAGE’s role at the intersection of inflammatory and metabolic signaling and suggest that inhibiting RAGE may offer a promising therapeutic avenue to mitigate obesity and its related comorbidities through both pharmacologic and lifestyle-based interventions. Here, AGER is linked to obesity due to melanocortin 4 receptor deficiency.